Skip to main content

Table 1 Characteristics of RCTs involved in the study

From: Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review

Study Patients Scra(mg/dl) Proteinuriaa(g/d) Systolic BP (mmHg) Sample sizeb MMF Control Follow–up (m) Drop-in/MMF discontinuation Other treatment regimen
Dose (g/d) Duration (m)
Chen et al. 2002 [20] Grades:IV-V with interstitial inflammation area > 25%; Proteinuria > 2 g/d NA MMF:3.2 ± 1.7; Control:2.9 ± 1.5 NA 62 (31/31) 1.0–1.5 12 Steroid 18 NA/0 CCB, antiplatelet when needed
Meas et al. 2004 [21] Grades:II-IV; Proteinuria > 1 g/d; Icr > 20 but < 70 mL/min/1.73 m2 MMF:1.46 ± 0.08 Control: 1.39 ± 0.1 MMF:1.9 ± 0.3; Control:1.3 ± 0.4 MMF:122 ± 4 Control:134 ± 8 34 (21/13) 2 36 Placebo 36 NA/1 Salt restriction, ACEI/ARB or CCB
Frisch et al. 2005 [22] Proteinuria > 1 g/d; Ccr > 20 but < 80 ml/min; glomerulosclerosis/tubulointerstitial fibrosis and/or crescent ≥25% MMF:2.6 ± 1.2 Control:2.2 ± 0.72 MMF:2.7 ± 1.6; Control:2.7 ± 1.4 MMF:136 ± 19.2 Control:131 ± 10.6 32 (17/15) Up to 2 g/d 12 Placebo 24 NA/0 ACEI/ARB
Tang et al. 2005 [23] Grades:II-IV; Proteinuria > 1 g/d; MMF:1.53 ± 0.17; Control:1.65 ± 0.23 MMF:1.8 ± 0.21; Control:1.87 ± 0.28 MMF:120 ± 3.2 Control:122 ± 3.2 40 (20/20) 1.5–2 6 Placebo 18 NA/0 Salt restriction; ACEI/ARB
Zhao et al. 2005 [24] Grades ≥ III All:1.6 ± 0.53 All:2.03 ± 0.67 NA 31 (21/10) 1.0–1.5 24 CTX 24 2/0 Prednisone 0.6 mg/kg.d in both groups; CCB or ACEI/ARB
Bao et al. 2007 [25] Crescentic nephropathy; crescent ≥15% MMF:1.21 ± 0.96; Control:1.15 ± 0.57 MMF:2.94 ± 2.11; Control:2.87 ± 1.69 NA 34 (18/16) 1.0–1.5 6 CTX 12 NA/0 Methylprednisolone 0.5 g iv for first 3ds, 0.8 mg/kg.d p.o. CCB or ACEI/ARB
Liu et al. 2010 [26] Nephritic syndrome MMF:1.09 ± 0.27; Control:1.04 ± 0.29 MMF:2.6 ± 1.2; Control:2.2 ± 0.72 NA 40 (20/20) 1.5 6 LEF 6 NA/0 Prednisone 0.8 mg/kg.d in both MMF and control;
Liu et al. 2014 [27] Proteinuria > 1 g/d; Scr < 3 mg/dl; CrCl > 50/1.73 m2 Grade ≥ III MMF:1.5 ± 0.4 Control:1.4 ± 0.4 MMF:2.83 ± 0.65 Control:2.77 ± 0.81 MMF:141 ± 15.4 Control:134 ± 17.7 84 (42/42) 1.5 g 18 CTX 18 NA/0 Prednisone 0.8–1.0 mg/kg.d in both groups; CCB or ACEI/ARB antiplatelet when needed
  1. Drop in, patients who are randomized to the standard/control arm but start taking/using the experimental treatment; Scr, serum creatinine; NA, not available; Icr, insulin clearance; Ccr, creatine clearance; UPC, urine protein-to-creatinine; CTX, cyclophosphamide; LEF, leflunomide; IQR, interquartile range.
  2. aExpressed as mean ± SD or median (IQR).
  3. bExpressed as total number of patients (number in steroid group/number in control group).